$0.90 Earnings Per Share Expected for Bausch Health Companies Inc (NYSE:BHC) This Quarter
Analysts expect that Bausch Health Companies Inc (NYSE:BHC) will post earnings per share (EPS) of $0.90 for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Bausch Health Companies’ earnings. The lowest EPS estimate is $0.75 and the highest is $1.00. Bausch Health Companies posted earnings per share of $1.03 during the same quarter last year, which would indicate a negative year-over-year growth rate of 12.6%. The company is expected to announce its next earnings report on Tuesday, August 4th.
On average, analysts expect that Bausch Health Companies will report full-year earnings of $3.74 per share for the current year, with EPS estimates ranging from $3.56 to $4.26. For the next financial year, analysts expect that the business will post earnings of $4.40 per share, with EPS estimates ranging from $3.94 to $4.94. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that that provide coverage for Bausch Health Companies.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.88 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.88. The firm had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $2.03 billion. Bausch Health Companies had a negative net margin of 21.96% and a positive return on equity of 84.58%. The business’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.03 EPS.
In other news, Director Holdings L.P. Valueact bought 948,353 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was acquired at an average price of $19.24 per share, with a total value of $18,246,311.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John Paulson bought 1,628,920 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were purchased at an average cost of $15.87 per share, with a total value of $25,850,960.40. The disclosure for this purchase can be found here. Insiders have purchased 4,618,309 shares of company stock valued at $79,509,247 in the last three months. 12.14% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Morgan Stanley increased its stake in Bausch Health Companies by 206.2% in the first quarter. Morgan Stanley now owns 13,614,293 shares of the company’s stock valued at $211,021,000 after purchasing an additional 9,167,662 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in Bausch Health Companies by 55.1% in the first quarter. The Manufacturers Life Insurance Company now owns 1,808,047 shares of the company’s stock valued at $27,704,000 after purchasing an additional 642,647 shares in the last quarter. Maverick Capital Ltd. increased its stake in Bausch Health Companies by 5.7% in the first quarter. Maverick Capital Ltd. now owns 153,038 shares of the company’s stock valued at $2,372,000 after purchasing an additional 8,240 shares in the last quarter. X Square Capital LLC bought a new stake in Bausch Health Companies in the first quarter valued at $2,081,000. Finally, Twinbeech Capital LP bought a new stake in Bausch Health Companies in the first quarter valued at $414,000. 68.94% of the stock is owned by institutional investors and hedge funds.
Bausch Health Companies stock traded up $0.10 during trading hours on Thursday, hitting $18.29. The company had a trading volume of 178,238 shares, compared to its average volume of 4,942,722. The firm has a market cap of $6.45 billion, a PE ratio of -3.39, a PEG ratio of 0.45 and a beta of 1.26. Bausch Health Companies has a one year low of $11.15 and a one year high of $31.97. The firm has a 50-day moving average of $18.28 and a 200 day moving average of $22.02.
Bausch Health Companies Company Profile
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.
Recommended Story: What is the Nikkei 225 index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.